Early activation antigen CD69 (CD69) (CD69)

Early activation antigen CD69 is a type II transmembrane glycoprotein belonging to the C-type lectin superfamily (UniProt P37217). It is one of the earliest cell surface markers expressed by Natural Killer (NK) cells, T cells, and B cells following activation (PubMed 25617461). In expanded NK cells (exp-NK), CD69 functions as an activating receptor that, upon ligation, triggers intracellular signaling pathways leading to enhanced cytotoxicity and the secretion of pro-inflammatory cytokines like IFN-gamma (PubMed 15123770). Beyond its role in activation, CD69 regulates lymphocyte migration by forming a complex with sphingosine-1-phosphate receptor 1 (S1P1), leading to its internalization and the subsequent retention of lymphocytes in lymphoid organs (PubMed 16518395). This mechanism makes CD69 a critical regulator of immune cell trafficking to inflammatory sites. In oncology, CD69 is explored as a target to boost NK cell-mediated anti-tumor immunity, while in autoimmune diseases, its inhibition is studied to prevent tissue infiltration by pathogenic leukocytes. Although no CD69-targeted therapies are currently FDA-approved, various monoclonal antibodies are in preclinical development for inflammatory conditions such as asthma and arthritis.

Other names

CLEC2CActivation inducer moleculeAIMEA1MLR3C-type lectin domain family 2 member C

Modulation of NK cell cytotoxicity and cytokine release; downregulation of S1P1-mediated lymphocyte egress.